Switch theme
Sign up to access all valuation multiples
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
2019
89
LTM Revenue $0.1M
Last FY EBITDA -$64.9M
-$105M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Artiva Biotherapeutics has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Artiva Biotherapeutics achieved revenue of $0.3M and an EBITDA of -$64.9M.
Artiva Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Artiva Biotherapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$64.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -25837% | XXX | XXX | XXX |
| EBIT | -$75.8M | XXX | -$67.3M | XXX | XXX | XXX |
| EBIT Margin | -51539% | XXX | -26806% | XXX | XXX | XXX |
| Net Profit | -$72.4M | XXX | -$58.5M | XXX | XXX | XXX |
| Net Margin | -49194% | XXX | -23304% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Artiva Biotherapeutics's stock price is $2.
Artiva Biotherapeutics has current market cap of $47.0M, and EV of -$105M.
See Artiva Biotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$105M | $47.0M | XXX | XXX | XXX | XXX | $-4.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Artiva Biotherapeutics has market cap of $47.0M and EV of -$105M.
Artiva Biotherapeutics's trades at -418.1x EV/Revenue multiple, and 1.6x EV/EBITDA.
Equity research analysts estimate Artiva Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Artiva Biotherapeutics has a P/E ratio of -0.6x.
See valuation multiples for Artiva Biotherapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $47.0M | XXX | $47.0M | XXX | XXX | XXX |
| EV (current) | -$105M | XXX | -$105M | XXX | XXX | XXX |
| EV/Revenue | -713.1x | XXX | -418.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBIT | 1.4x | XXX | 1.6x | XXX | XXX | XXX |
| EV/Gross Profit | -713.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArtiva Biotherapeutics's revenue per employee in the last FY averaged $3K, while opex per employee averaged $0.8M for the same period.
Artiva Biotherapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Artiva Biotherapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Artiva Biotherapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -25837% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20051% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 26906% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Artiva Biotherapeutics acquired XXX companies to date.
Last acquisition by Artiva Biotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Artiva Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Artiva Biotherapeutics founded? | Artiva Biotherapeutics was founded in 2019. |
| Where is Artiva Biotherapeutics headquartered? | Artiva Biotherapeutics is headquartered in United States of America. |
| How many employees does Artiva Biotherapeutics have? | As of today, Artiva Biotherapeutics has 89 employees. |
| Who is the CEO of Artiva Biotherapeutics? | Artiva Biotherapeutics's CEO is Dr. Fred Aslan, M.D.. |
| Is Artiva Biotherapeutics publicy listed? | Yes, Artiva Biotherapeutics is a public company listed on NAS. |
| What is the stock symbol of Artiva Biotherapeutics? | Artiva Biotherapeutics trades under ARTV ticker. |
| When did Artiva Biotherapeutics go public? | Artiva Biotherapeutics went public in 2024. |
| Who are competitors of Artiva Biotherapeutics? | Similar companies to Artiva Biotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Artiva Biotherapeutics? | Artiva Biotherapeutics's current market cap is $47.0M |
| What is the current revenue of Artiva Biotherapeutics? | Artiva Biotherapeutics's last 12 months revenue is $0.1M. |
| What is the current EV/Revenue multiple of Artiva Biotherapeutics? | Current revenue multiple of Artiva Biotherapeutics is -713.1x. |
| Is Artiva Biotherapeutics profitable? | Yes, Artiva Biotherapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
